Westfield Capital Management
FATE icon

Westfield Capital Management’s Fate Therapeutics FATE Stock Holding History

Westfield Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,386,058
Closed -$14M – 235
2022
Q4 		$14M Sell
1,386,058
-5,159
-0.4% -$96.9K 0.11% 168
2022
Q3 		$31.2M Sell
1,391,217
-403,031
-22% -$11.6M 0.25% 142
2022
Q2 		$44.5M Buy
1,794,248
+573,927
+47% +$15.8M 0.35% 101
2022
Q1 		$47.3M Buy
1,220,321
+740,673
+154% +$28.7M 0.3% 117
2021
Q4 		$28.1M Buy
479,648
+188,547
+65% +$10.7M 0.17% 154
2021
Q3 		$17.3M Sell
291,101
-10,550
-3% -$828K 0.1% 174
2021
Q2 		$26.2M Buy
301,651
+44,934
+18% +$3.62M 0.16% 167
2021
Q1 		$21.2M Buy
256,717
+97,078
+61% +$9.3M 0.13% 172
2020
Q4 		$14.5M Sell
159,639
-250,690
-61% -$15.6M 0.09% 183
2020
Q3 		$16.4M Sell
410,329
-27,994
-6% -$977K 0.11% 177
2020
Q2 		$15M Buy
438,323
+26,227
+6% +$782K 0.1% 184
2020
Q1 		$9.15M Sell
412,096
-292,747
-42% -$7.4M 0.08% 178
2019
Q4 		$13.8M Sell
704,843
-200,776
-22% -$3.19M 0.1% 178
2019
Q3 		$14.1M Buy
905,619
+46,870
+5% +$898K 0.11% 174
2019
Q2 		$17.4M Sell
858,749
-34,676
-4% -$625K 0.13% 182
2019
Q1 		$15.7M Sell
893,425
-210,880
-19% -$3.33M 0.12% 187
2018
Q4 		$14.2M Buy
1,104,305
+272,235
+33% +$3.8M 0.12% 177
2018
Q3 		$13.6M Buy
832,070
+26,610
+3% +$315K 0.1% 191
2018
Q2 		$9.13M Buy
+805,460
New +$8.87M 0.07% 205

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Westfield Capital Management's FATE Position: Q1 2023 in Review

Westfield Capital Management sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 1,386,058 shares — an estimated $14M sold.

Westfield Capital Management first reported a position in FATE in Q2 2018 and held it in 19 quarters. The position peaked at $47.3M in Q1 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Westfield Capital Management reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Westfield Capital Management sold 1,386,058 Fate Therapeutics shares in Q1 2023, an estimated $14M.
  • Westfield Capital Management first reported a position in Fate Therapeutics in Q2 2018 and held it in 19 quarters.
  • Westfield Capital Management's Fate Therapeutics position peaked at $47.3M in Q1 2022.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Westfield Capital Management's 13F filing for Q1 2023, filed 12 May 2023.